POWER SOLUTIONS INTERNATIONAL, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that POWER SOLUTIONS INTERNATIONAL, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $131.48M | May 16, 2019 |
| FY2017 | Sep 30, 2017 | $99.95M | May 16, 2019 |
| FY2017 | Jun 30, 2017 | $100.92M | May 16, 2019 |
| FY2017 | Mar 31, 2017 | $84.27M | May 16, 2019 |
| FY2017 | Dec 31, 2016 | $98.28M | May 16, 2019 |
| FY2017 | Sep 30, 2016 | $78.94M | May 16, 2019 |
| FY2017 | Jun 30, 2016 | $85.77M | May 16, 2019 |
| FY2017 | Mar 31, 2016 | $76.47M | May 16, 2019 |
| FY2017 | Dec 31, 2015 | $362.39M | May 16, 2019 |
| FY2017 | Dec 31, 2014 | $347.58M | May 16, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $722.41M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $475.97M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $458.97M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $481.33M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $456.26M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $417.64M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $546.08M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $138.23M | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | $136.32M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $127.07M | Dec 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $140.54M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $105.86M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $88.56M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $41.27M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $58.45M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $99.89M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $12.02M | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | $18.81M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $18.07M | Dec 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.99M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $69.28M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $26.31M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $11.27M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($48.47M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($22.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.25M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | ($9.90M) | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | ($18.82M) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | ($11.81M) | Dec 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.71M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $81.64M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $44.28M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $24.60M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($41.57M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($21.72M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $17.20M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | ($16.17M) | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | ($6.60M) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | ($3.49M) | Dec 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.16M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $20.06M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $19.46M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $18.90M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $22.44M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $25.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $24.93M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $7.91M | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | $7.71M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $6.96M | Dec 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $62.39M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $70.51M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($8.85M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($61.48M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($7.59M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.16M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($6.17M) | May 4, 2020 |
| FY2018 | Sep 30, 2018 | ($3.67M) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | ($8.19M) | Dec 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $424.75M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $328.18M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $284.30M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $319.91M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $300.54M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $283.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $313.67M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $289.88M | May 4, 2020 |
| FY2018 | Sep 30, 2018 | $292.69M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $274.12M | Dec 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.14M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $262.93M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $288.22M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $350.29M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $342.56M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $277.88M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $285.18M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $308.46M | May 4, 2020 |
| FY2018 | Sep 30, 2018 | $301.96M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $265.19M | Dec 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $178.61M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $65.25M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($3.92M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($30.37M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | ($42.02M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $6.10M | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | $28.50M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($18.58M) | Mar 30, 2021 |
| FY2018 | Sep 30, 2018 | ($9.27M) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $8.93M | Dec 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.84M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $29.84M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $29.84M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $29.84M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $29.84M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $29.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $29.84M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $29.84M | May 4, 2020 |
| FY2018 | Sep 30, 2018 | $29.84M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $29.84M | Dec 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.48M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($91.51M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($160.79M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($187.10M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($198.37M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($149.89M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($126.91M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($135.16M) | May 4, 2020 |
| FY2018 | Sep 30, 2018 | ($125.26M) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | ($106.44M) | Dec 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.25M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $55.25M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $22.76M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $24.30M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $6.26M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $20.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $54.0K | May 4, 2020 |
| FY2018 | Sep 30, 2018 | $2.01M | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | $2.0K | Dec 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $184.0K | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | $5.20M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $25.64M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $781.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $55.66M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $55.09M | May 4, 2020 |
| FY2018 | Dec 31, 2017 | $54.44M | Dec 27, 2019 |
| FY2017 | Dec 31, 2016 | $110.39M | May 16, 2019 |
| FY2017 | Dec 31, 2015 | $151.10M | May 16, 2019 |
| FY2017 | Dec 31, 2014 | $80.39M | May 16, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Dec 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Dec 27, 2019 |
| FY2018 | Sep 30, 2018 | (1) | Dec 27, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Dec 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.04M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 23.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 22.97M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 22.95M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 22.93M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 22.89M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | 22.86M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | 18.64M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | 18.43M | May 4, 2020 |
| FY2018 | Dec 31, 2016 | 10.92M | Dec 27, 2019 |